Definium Therapeutics, Inc. (DFTX) stock
DFTXNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
$32.08−0.92 (-2.79%)
Close on Nov 13, 2026Market cap $4.31BP/E –Yield –
Definium Therapeutics cash
Cash and short-term investments held at the end of each period.
Definium Therapeutics's cash was $1.05B at Sep 30, 2026. For fiscal 2025 it was $411.59M, up 50.4% from the year before. The highest annual figure on record is $411.59M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $411.59M | +50.4% |
| FY2024 | Dec 31, 2024 | $273.74M | +174.6% |
| FY2023 | Dec 31, 2023 | $99.70M | -29.9% |
| FY2022 | Dec 31, 2022 | $142.14M | +6.4% |
| FY2021 | Dec 31, 2021 | $133.54M | +66.7% |
| FY2020 | Dec 31, 2020 | $80.09M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.05B | +400.7% |
| Q2 FY2026 | Jun 30, 2026 | $1.08B | +492.3% |
| Q1 FY2026 | Mar 31, 2026 | $373.42M | +75.8% |
| Q4 FY2025 | Dec 31, 2025 | $411.59M | +50.4% |
| Q3 FY2025 | Sep 30, 2025 | $209.07M | -29.2% |
| Q2 FY2025 | Jun 30, 2025 | $182.99M | -24.7% |
| Q1 FY2025 | Mar 31, 2025 | $212.44M | -15.8% |
| Q4 FY2024 | Dec 31, 2024 | $273.74M | +174.6% |
| Q3 FY2024 | Sep 30, 2024 | $295.28M | +150.9% |
| Q2 FY2024 | Jun 30, 2024 | $243.13M | +108.0% |
| Q1 FY2024 | Mar 31, 2024 | $252.33M | +95.0% |
| Q4 FY2023 | Dec 31, 2023 | $99.70M | -29.9% |
| Q3 FY2023 | Sep 30, 2023 | $117.70M | -23.8% |
| Q2 FY2023 | Jun 30, 2023 | $116.90M | +10.5% |
| Q1 FY2023 | Mar 31, 2023 | $129.41M | +7.4% |
| Q4 FY2022 | Dec 31, 2022 | $142.14M | +6.4% |
| Q3 FY2022 | Sep 30, 2022 | $154.52M | +92.9% |
| Q2 FY2022 | Jun 30, 2022 | $105.74M | – |
| Q1 FY2022 | Mar 31, 2022 | $120.47M | – |
| Q4 FY2021 | Dec 31, 2021 | $133.54M | – |
| Q4 FY2020 | Dec 31, 2020 | $80.09M | – |
See a number that looks wrong?